

COVID-19 Vaccine Recommendations

Booster Doses

Date: September 1, 2022



Everyone ages 12 years and older is recommended to receive ONE age-appropriate bivalent mRNA booster dose at least 2 months after completion of any FDA-approved or FDA-authorized monovalent primary series or last monovalent booster dose.

- People cannot receive a bivalent booster dose without first completing a primary series of a monovalent vaccine product.
- Age-appropriate homologous and heterologous boosters are allowed; there is no preference.
 - Pfizer bivalent booster → authorized for 12 years and older
 - Moderna bivalent booster → authorized for 18 years and older

Bivalent booster doses are authorized as a single booster dose administered at least 2 months after either:

- Completion of primary vaccination with **any** authorized or approved monovalent COVID-19 vaccine, or
- Receipt of the most recent booster dose with **any** authorized or approved monovalent COVID-19 vaccine.

Vaccination History	→	Next dose
Primary series	At least 2 months →	1 bivalent booster dose
Primary series + 1 booster	At least 2 months →	1 bivalent booster dose
Primary series + 2 boosters	At least 2 months →	1 bivalent booster dose

- The new bivalent booster recommendations **replace** previous booster recommendations for people ages 12 years and older.
 - Fall Booster “Reset” → moving forward, recommendations will be simplified.
 - Change from “dose counting” (ex. dose 4, dose 5, etc.) to ONE bivalent booster for everyone eligible.
- Monovalent vaccine products must still be used for **primary series** doses.
- Monovalent vaccine products are **no longer authorized for use as booster doses** for patients 12 years and older.
- Recommendations for COVID-19 vaccines for ages 6 months through 11 years have not changed.
 - Patients ages 5 years to 11 years who received a primary series of Pfizer should still receive ONE booster dose of the *monovalent* Pfizer product for this age group.